Q3 2024 Praxis Precision Medicines Inc Earnings Call Transcript
Key Points
- Praxis Precision Medicines Inc (PRAX) is advancing four programs towards registration, representing a substantial multi-billion dollar opportunity.
- The phase three study for Ulixacaltamide in essential tremor is progressing well, with results expected in Q1 2025.
- Positive top-line results were reported for Vormatrigine in a phase two trial, showing a 46% reduction in motor seizures versus placebo.
- The company has a strong balance sheet with $411.2 million in cash, supporting operations into 2027.
- Praxis Precision Medicines Inc (PRAX) has initiated a second registrational cohort for Vormatrigine, indicating strong momentum in their clinical programs.
- The interim analysis for the essential tremor study has been delayed to Q1 2025, which may impact timelines.
- There is uncertainty regarding the enrollment criteria and potential changes in the expanded cohort for Relugolix in epilepsy.
- The company faces challenges in managing placebo responses in decentralized trials, which could affect study outcomes.
- The commercial potential outside the US is considered opportunistic, indicating potential limitations in global market reach.
- There are concerns about the influence of study one results on study two in the essential tremor program, which could impact the overall program integrity.
Good day and thank you for standing by. Welcome to the Practice Precision Medicines third quarter, 2024 corporate update. (Operator Instructions) I would now like to hand the conference over to your speaker today, Dan Ferry from Lifesci.
Good morning and welcome to the Practice Precision Medicines third quarter, 2024 financial results and business update conference call.
This call is being webcast live and can be accessed on the investors section of the Practice website at www. Practice medicines.com.
Please note that remarks made during this call may contain forward-looking statements within the meeting of the Private Securities Litigation Reform Act of 1,995.
These may include statements about the company's future expectations and plans, clinical development timelines and financial projections.
While these forward-looking statements represent practices view as of today, they should not be relied upon as representing the company's views in the future. Practice may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
